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ZAP-70 expression is associated with increased risk of autoimmune
cytopenias in CLL patients
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Autoimmune cytopenias (AIC) are frequent in chronic lymphocytic leukemia (CLL) patients, but risk factors
and prognostic relevance of these events are controversial. Data about the inﬂuence on AIC of biological prog-
nostic markers, as ZAP-70, are scanty. We retrospectively evaluated AIC in 290 CLL patients tested for ZAP-70
expression by immunohistochemistry on bone marrow biopsy at presentation. They were 185 men, median
age 63 years, 77.9% Binet stage A, 17.6% B and 4.5% C. AIC occurred in 46 patients (16%): 31 autoimmune he-
molytic anemias, 10 autoimmune thrombocytopenias, four Evans syndromes, and one pure red cell aplasia.
Of the 46 cases of AIC, 37 (80%) occurred in ZAP-70 positive patients and nine (20%) in ZAP-70 negatives.
ZAP-70 expression [Hazard Ratio (HR) 5 7.42; 95% conﬁdence interval (CI): 2.49–22.05] and age >65 years (HR
5 5.41; 95% CI: 1.67–17.49) resulted independent risk factors for AIC. Among the 136 patients evaluated both
for ZAP-70 expression and IGHV status, the occurrence of AIC was higher in ZAP-70 positive/IGHV unmutated
cases (35%) than in patients ZAP-70 negative/IGHV mutated (6%) or discordant for the two parameters (4%;
P < 0.0001). In ZAP-70 positive patients, occurrence of AIC negatively inﬂuenced survival (HR 5 1.75; 95% CI:
1.06–2.86). The high risk of developing AIC in ZAP-70 positive CLL, particularly when IGHV unmutated, should
be considered in the clinical management. Am. J. Hematol. 85:494–498, 2010. VC 2010 Wiley-Liss, Inc.
Introduction
Chronic lymphocytic leukemia (CLL) is known to be char-
acterized by a profound dysregulation of the immune sys-
tem, including autoimmune phenomena. The most frequent
autoimmune complications in CLL are directed against
blood cell antigens producing autoimmune cytopenias
(AIC), namely autoimmune hemolytic anemia (AIHA), auto-
immune thrombocytopenia (AITP) and, more rarely, pure
red cell aplasia (PRCA). Of them, AIHA is the most com-
mon, with a reported prevalence in recent studies ranging
from 3% to 10% [1–5]. AITP is estimated to be less fre-
quent than AIHA in CLL, with an overall prevalence around
2%–5% [5–7]. About a third of AITP is associated with
AIHA (Evans’ Syndrome) [8]. PRCA associated with CLL is
quite rare, whereas the occurrence of immune neutropenia
in CLL is disputed [8].
The prognostic relevance of AIHA occurrence in CLL
patients is controversial (1–4,9), whereas AITP has been
reported to be associated with inferior overall survival (OS) [6].
Older age, male sex, advanced stage, high lymphocyte
count, and previous heavy treatment were reported to be
associated to higher risk of AIHA, high lymphocyte count
and positivity of direct antiglobulin test (DAT) with AITP
[1,6,9,10]. The reported increased risk of AIHA after treat-
ment with purine analogues has recently been questioned
[3,9–12].
The correlation of CLL biological prognostic markers, as
ZAP-70 expression and IGHV gene mutational status, with
occurrence of AIC is uncertain, with the exception of the
reported increased incidence of AITP in IGHV unmutated
patients [6].
ZAP-70 protein expression in leukemic cells has been
validated as reliable and independent marker capable of
strongly inﬂuencing both progression-free survival and OS
in CLL. Various techniques were used for testing ZAP-70
expression, including ﬂow cytometry and immunohisto-
chemistry (IHC) [13–17]. Although ﬂow cytometry is com-
monly used, IHC was demonstrated to be a reliable method
for this purpose [16–18].
To assess a possible correlation between ZAP-70
expression and other clinical and biological prognostic
factors of CLL and the risk of AIC, we analyzed our CLL
patients tested for ZAP-70 expression by IHC on bone
marrow (BM) biopsy at presentation.
Patients and Methods
Patients. We retrospectively evaluated 290 patients referring to the
Hematology Department of Verona and diagnosed as CLL between
June 1989 and December 2008, selected on the basis of the availability
of ZAP-70 expression by leukemic cells tested by IHC on BM biopsy,
performed within 6 months from diagnosis, and before any treatment.
Approval was obtained from the Azienda Ospedaliera of Verona insti-
tutional review board for this study.
Diagnosis of CLL was based or revised according to recent morpho-
logical and immunophenotypical criteria [19]. They were 185 men
(64%) and 105 women, aged 33–85 years (median 63). At diagnosis,
226 patients were classiﬁed as Binet stage A (77.9%), 51 stage B
(17.6%), and 13 stage C (4.5%). The median follow-up from diagnosis
was 80 months (range 12–240 months). The ﬁnding at diagnosis of
anemia or thrombocytopenia because of autoimmune phenomena was
not considered as criteria for classifying patients as Binet stage C.
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Diagnostic criteria for AIC. AIHA was diagnosed in patients with a
drop in Hb level below 10 gr/dl, associated with positive DAT for either
IgG or complement fragment C3d and the presence of one or more
indicators of hemolysis (increased indirect bilirubin and/or LDH,
decreased haptoglobin, increased absolute reticulocyte count), with no
other cause for anemia identiﬁed.
The diagnosis of AITP was made in patients with platelets <100 3
109 with no evidence of hypersplenism, nor decreased BM platelet pro-
duction (normal or increased megakaryocytes on BM examination) and
no cytotoxic treatment in the last month [2,5].
The diagnosis of PRCA was based on Hb <10 gr/dl, reticulocytope-
nia (<10 3 109/L) and isolated absence of erythroid precursors in BM
aspirate or biopsy.
Patients developing different types of AIC during the disease course
were classiﬁed according to the ﬁrst episode occurred.
Treatment. Before the occurrence of AIC, 170 patients had been
treated, of whom 71 with chlorambucil alone, 33 with ﬂudarabine com-
bined with cyclophosphamide (FC) and 66 with two or more lines of
therapy (mostly chlorambucil followed by ﬂudarabine or FC).
ZAP-70 evaluation by IHC. In all patients, ZAP-70 expression was
evaluated on BM biopsies taken at diagnosis. The method of IHC has
been already published in detail [17]. The pattern of BM involvement
was categorized according to Rozman et al. [20].
ZAP-70 and CD38 evaluation by ﬂow cytometry. Evaluation of ZAP-70
and of CD38 by ﬂow cytometry was performed in 181 and 209 patients,
respectively. The method of ﬂow cytometry has been already published
in detail [17]. The cut-off value was set at 20% of ZAP-70 and at 7% of
CD38 positive B-CLL cells, identiﬁed as CD191/CD51 cells [21].
Determination of IGHV gene mutational status. IGHV mutational sta-
tus was assessed in leukemic cells of 136 patients obtained from fro-
zen or fresh peripheral blood (PB) samples collected at diagnosis after
isolation by Ficoll gradient, as previously described [17]. The sequen-
ces with a germline homology 98% were considered unmutated, and
those <98% mutated [22].
Statistical analysis. The comparison of presenting clinical and labo-
ratory features between the groups of patients with and without AIC
was carried out with the chi-square test, Fisher exact test or Mann-
Whitney test as appropriate. OS was deﬁned as the time from diag-
nosis of CLL to death or last follow-up. Time to AIC was deﬁned as
the time from diagnosis of CLL to occurrence of the ﬁrst episode of
AIC or last follow-up or death.
OS and time to AIC curves were estimated according to the Kaplan-
Meier method. The association with prognostic factors was tested using
the log-rank test. Univariate and multivariate analyses were performed
using the Cox regression model, to obtain unadjusted and adjusted
hazard ratios (HRs) and their 95% conﬁdence intervals (95% CIs). All
tests were bilateral at P < 0.05. The statistical analyses were per-
formed using StatView (Abacus Concepts, Berkeley, CA).
Results
Patient’s data
Forty-six of 290 patients (16%) developed AIC. Clinical and
laboratory characteristics of these patients are listed in Table I.
The most frequent form of AIC was AIHA because of
warm autoantibodies (31 cases—11%), followed by AITP
(10 cases—3%), Evans syndrome (4 cases—1%), and
PRCA (1 case—0.3%). No cases of cold haemagglutinin
diseases were recorded. The median age at occurrence of
AIC was 67 years (range 41–85).
AIC occurred at diagnosis in 7 of 46 patients (15%) (four
AIHA, two AITP, and one PRCA); in the remaining 39
patients, the median time from diagnosis to AIC was 52
months (range 4–147). AIHA and AITP developed after a
median time from diagnosis of 58 (range 0–112) and 41
(range 0–147) months, respectively (Fisher exact test: P 5
ns). Four patients had alternated episodes of AIHA and
AITP during the observation period.
The 7-year actuarial cumulative incidence of AIC was
17% and that of AIHA and AITP, 13% and 3%, respectively.
ZAP-70 evaluation by IHC on BM biopsies. Homoge-
neous cytoplasmic and/or nuclear ZAP-70 expression in
neoplastic B lymphocytes was detected in 142 of 290
cases (49%).
ZAP-70 and CD38 evaluation by ﬂow cytometry. ZAP-
70 was expressed in 20% of B-CLL cells in 92 of 181
tested cases (51%). ZAP-70 expression evaluated both by
IHC and ﬂow cytometry was concordant in 160 of 181
cases (88%) and, particularly, in 21 of 22 patients with AIC
evaluated with both techniques.
CD38 was expressed in 7% of B-CLL cells in 114 of
209 tested cases (56%).
IGHV gene mutational status. In 69 of the 136 patients
(51%) tested, the expressed IGHV gene showed 98% or
greater identity with a known germ-line IGHV gene. IGHV
gene mutational status was concordant with ZAP-70 expres-
sion evaluated by IHC in 110 of 136 patients (81%). Of the
26 discordant cases, 16 (12%) were IGHV mutated and
ZAP-70 positive, 10 (7%) unmutated and ZAP-70 negative.
Association of AIC with clinical and biological prog-
nostic parameters evaluated at diagnosis. Clinical fea-
tures at diagnosis of patients who developed AIC compared
with those of the remaining patients are detailed in Table I.
Patients with AIC had signiﬁcantly lower male/female ratio,
higher PB lymphocyte count, and more frequent diffuse BM
inﬁltration, unmutated IGHV genes, and expression of ZAP-
70. No signiﬁcant difference was found concerning Binet
stage, age, and CD38 expression. Patients who developed
AIHA and AITP, respectively, did not signiﬁcantly differ
according to the clinical and biological parameters eval-
uated at diagnosis (data not shown).
As shown in Table II, female sex, age >65 years,
Binet stage B-C, PB lymphocyte count  30 3 109/L,
B2MG levels >2 mg/dl, diffuse BM inﬁltration, ZAP-70
expression by IHC and unmutated IGHV status were
associated with increased risk of developing AIC at uni-
variate analysis. Only CD38 expression did not correlate
with time to AIC.
Associations with increased occurrence of AIC were con-
ﬁrmed by adjusted Cox model for ZAP-70 expression (HR
5 7.42; 95% CI: 2.49–22.05) and age >65 years (HR 5
4.62; 95% CI: 1.9–11.22). IGHV genes mutational status
was not included in Cox model because of the fact that
was evaluated only in 136 of 290 patients and because of
its high concordance rate with ZAP-70 expression in
patients who developed AIC (92%).
Thirty-seven of the 46 cases of AIC occurred in ZAP-70
positive patients (80%) and nine in ZAP-70 negatives
TABLE I. Characteristics at Diagnosis of 290 CLL Patients
According to Occurrence of AIC
Parameters
CLL without
AIC (n 5 244)
CLL with
AIC (n 5 46) P
Male sex 163 (66.8%) 22 (47.8%) 0.018a
Male/female ratio 2.01 0.92
Median age, yr (range) 62 (33–83) 66 (35–80) 0.235b
Binet stage
A 189 (77.5%) 31 (67.4%)
B 46 (18.8%) 11 (23.9%) 0.203c
C 9 (3.7%) 4 (8.7%)
PB Lymphocyte,
mean ± SE 3109/L
20.1 ± 1.6 27.6 ± 4.6 0.037b
Beta2microglobulin,
mean ± SE mg/dl
1.97 ± 0.1 2.33 ± 0.3 0.258b
Diffuse BM inﬁltration 77 (31.6%) 22 (47.8%) 0.041a
CD38 positivity by ﬂow
cytometry (7% B cells)d
94 (54.0%) 20 (57.1%) 0.852a
ZAP-70 positivity by IHC 105 (43.0%) 37 (80.4%) <0.0001a
IGHV unmutated (98% homology)e 51 (45.9%) 18 (72.0%) 0.026a
Statistically signiﬁcant (P < 0.05) values are indicated in bold.
AIC, autoimmune cytopenia; PB, peripheral blood; BM, bone marrow; IHC,
immunohistochemistry.
a
Fisher exact test; bMann-Whitney test; c chi-square test; d Values available in
209 patients; e Values available in 136 patients.
American Journal of Hematology 495
research article
(20%). Characteristics of patients who developed AIC
according to ZAP-70 expression were detailed in Table III.
In particular, ZAP-70 negative cases did not differ from
ZAP-70 positives with respect to age and stage at diagno-
sis, sex, and type of AIC. As expected, ZAP-70 positive
patients were mostly CD38 positive and IGHV unmutated.
The 7-years projected cumulative incidence of AIC in
ZAP-70 positive patients was 30% vs 4% of ZAP-70 nega-
tives (P < 0.0001) (Fig. 1).
Of the 25 patients with AIC tested for IGHV mutational
status, 18 (72%) resulted unmutated and 7 (28%) mutated.
Among the 136 patients tested for the mutational status,
the 7-years occurrence of AIC in the 59 ZAP-70 positive/
IGHV unmutated cases was higher (35%) as compared
with that of the 51 ZAP-70 negative/IGHV mutated patients
(6%) and of the 26 patients discordant for the two prognos-
tic parameters (4%) (P 50.0004; Fig. 2). The two discord-
ant patients who developed AIC were both ZAP-70 positive/
IGHV mutated.
Association of AIC and treatment of CLL. The occur-
rence of AIC was not signiﬁcantly different among
untreated or treated patients and among those who
received one or more lines of therapy.
AIC occurred in 28 treated patients: in detail, in 18 of 71
(25%) patients treated only with Chlorambucil, in 4 of 18
(22%) who received ﬂudarabine alone and in 6 of 79 (8%)
treated with FC (v2 test: P 5 0.011).
Overall Survival. We observed 87 disease- or treat-
ment-related deaths (30%) and only three deaths in
untreated patients for unrelated causes. The 10-years pro-
jected OS was 60%.
Among the clinical and biological markers that have been
widely recognized as adverse prognostic factors in CLL
patients at diagnosis, univariate analysis revealed age >65
years (P 5 0.029), B-C Binet stage (P < 0.0001), PB lym-
phocyte count 30 3 109/L (P 5 0.010), B2MG levels >2
mg/dl (P < 0.0001), diffuse BM inﬁltration (P 5 0.0011),
ZAP-70 expression (P < 0.0001), CD38 positivity (P 5
0.0004), and unmutated IGHV status (P < 0.0001), as
adverse factors in terms of OS. As shown in Fig. 3,
patients who experienced AIC during the observation
period had a 10-year OS inferior (34%) than patients with-
out AIC (67%; HR 5 2.28; 95% CI: 1.46–3.56).
At multivariate analysis, AIC lost independent predictive
power (HR 5 1.21; 95% CI: 0.63–2.32) when computed in
the Cox model with all clinical and biologic variables that
resulted signiﬁcant at univariate analysis. Only B-C Binet
stage (HR 5 2.57; 95% CI: 1.35–4.89), age >65 years
(HR 5 2.01; 95% CI: 0.92–3.72), and ZAP-70 expression
(HR 5 2.90; 95% CI: 1.47–5.73) maintained a signiﬁcant
impact on OS. When we stratiﬁed the patients according to
ZAP-70 expression, occurrence of AIC demonstrated an
adverse impact on survival only in ZAP-70 positive patients
(HR 5 1.75; 95% CI: 1.06–2.86) but not in ZAP-70 nega-
tive patients (Fig. 4).
TABLE II. Effect of Prognostic Factors on Time to AIC:
Univariate and Multivariate Analysis (Hazard Ratio—95% CI)
Variable
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Female sex 1.77 (1.00–3.16) 1.44 (0.62–3.31)
Age >65 years 2.08 (1.15–3.73) 4.62 (1.9–11.22)
Binet stage B–C 2.28 (1.19–4.35) 0.91 (0.31–2.71)
PB lymphocyte
count  30 3 109/L
2.34 (1.26–4.34) 2.62 (0.99–6.96)
Beta2microglobulin >2 mg/dl 2.83 (1.23–6.48) 0.30 (0.48–2.14)
Diffuse BM inﬁltration 2.26 (1.21–4.10) 1.28 (0.50–3.25)
CD38 positivity by ﬂow
cytometry (7% B cells)a
1.20 (0.61–2.34) –
ZAP-70 expression by IHC 5.94 (2.83–12.47) 7.42 (2.49–22.05)
IGHV unmutated
(98% homology)b
3.80 (1.55–9.30) –
Statistically signiﬁcant (P < 0.05) values are indicated in bold.
AIC, autoimmune cytopenia; PB, peripheral blood; BM, bone marrow, IHC,
immunohistochemistry.
a
Values available in 209 patients; b Values available in 136 patients.
TABLE III. Characteristics of Patients Who Developed AIC,
According to ZAP-70 Expression
Parameters
ZAP-70
negative (9 pts)
ZAP-70
positive (37 pts) P
Male/female ratio 0.8 1.2 0.71a
Median age, yr (range) 61 (35–78) 66 (42–80) 0.57b
B–C Binet stage (%) 2 (22) 12 (32) 0.70a
CD38 positivity by
ﬂow-cytometry (7% B cells)d (%)
2 (22) 18 (69) 0.021a
IGHV unmutated
(98% homology)e (%)
0 (0) 18 (90) <0.0001a
Type of AIC (%)
AIHA 6 (67) 25 (68)
AITP 3 (33) 7 (19) 0.59c
Evans syndrome 0 4 (11)
PRCA 0 1 (2)
Median follow-up, months (range) 136 (12–240) 91 (18–202) 0.22b
Median time from diagnosis
to occurrence of AIC, months (range)
75 (0–192) 41 (0–108) 0.31b
AIHA: autoimmune haemolytic anaemia; AITP: autoimmune thrombocytopenia;
PRCA: pure red cell aplasia.
a
Fisher’s exact test; bMann-Whitney; c chi-square test; d Values available in 35
patients; e Values available in 25 patients.
Figure 1. Time to autoimmune cytopenia from CLL diagnosis according to ZAP-
70 expression (290 patients).
Figure 2. Time to autoimmune cytopenia from CLL diagnosis according to ZAP-
70 expression and IGHV genes mutational status (136 patients).
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Discussion
Hematological autoimmune complications are known to
be frequent in CLL, being reported in up to 25% of patients
during the disease course [7,8].
AIHA is recognized as the commonest hematological
autoimmune complication in CLL [8]. The prevalence of
AIHA we observed (11%) was higher as compared with
some recent studies (1–3,5); this ﬁnding could be related
not only to a possible selection of cases, but also to the
long follow-up period of our patients. In fact, in our series
AIHA occurred after a median time from diagnosis of 58
months. The prevalence of AITP (3%) we observed is com-
parable with that reported in the literature [6,8].
In our series, patients who developed AIC had lower
male/female ratio, higher PB lymphocytes count, more fre-
quent diffuse BM inﬁltration as compared with patients with-
out AIC. Moreover, they had more frequently unmutated
IGHV genes and positive expression of ZAP-70. At multi-
variate analysis, time to AIC was signiﬁcantly correlated
only with age >65 years and ZAP-70 expression. Other
parameters reported as factors associated with AIC as
B2MG, advanced stage, high lymphocyte count
[1,6,9,10,23] did not result signiﬁcant when combined in the
Cox model with ZAP-70 expression. IGHV genes muta-
tional status was not included in Cox model because of the
fact that it was evaluated only in about half of patients.
ZAP-70 expression is usually tested on PB lymphocytes
by ﬂow cytometry, although this approach still presents
standardization problems [24,25]. To assess ZAP-70
expression, we utilized immunohistochemical analysis on
BM biopsies. The reliability of this technique and the close
correlation between ZAP-70 as detected by IHC in BM
biopsies and PFS and OS in CLL patients have been previ-
ously demonstrated [17,18]. Moreover, this IHC method of
evaluation of ZAP-70 using formalin ﬁxed BM biopsies
taken at diagnosis allowed the retrospective evaluation of
patients with long follow-up. In our series, ZAP-70 expres-
sion tested by IHC and ﬂow cytometry, respectively, was
concordant in 89% of cases. The possibility of discordance
between the two methods probably did not inﬂuence our
results: in fact in all but one of the 22 patients with AIC,
analyzed with both techniques, ZAP-70 expression results
were concordant. The concordance rate of ZAP-70 expres-
sion evaluated by IHC and IGHV mutational status we
observed (81%) was comparable with reported data that
range between 77% and 92%, depending on the different
series and techniques [13–15,17,26].
We found ZAP-70 expression evaluated by IHC in 80%
of patients with AIC; similar results are so far reported only
in a small series of ﬁve AIHA [5]. The 7-year cumulative
incidence of AIC in ZAP-70 positive patients was 30% vs
4% of ZAP-70 negatives (P < 0.0001).
In our series, an IGHV genes unmutated status was
documented in 72% of patient with AIC, in keeping with a
previous report of 13 of 20 CLL patients with AIHA (65%)
and 15 of 20 patients (75%) with AITP [5,27] Moreover,
with the limit of the fact that evaluation was performed only
in about 50% of cases, CLL patients with both ZAP-70
expression and unmutated IGHV genes presented a inci-
dence of AIC at 7-years (35%) signiﬁcantly superior to that
of ZAP-70 negative patients with mutated genes (6%) and
of patients discordant for the two prognostic parameters
(4%; P < 0.0004).
The pathogenesis of AIC in CLL is still unclear. These
autoimmune hematological phenomena are usually caused
by polyclonal IgG autoantibodies produced by nonmalignant
B-lymphocytes and different from the Ig secreted by leuke-
mic cells. In CLL, AIC are probably linked to the profound
immune dysfunction that characterizes this disease, partic-
ularly in advanced phases. It has been hypothesized that
autoimmune phenomena could be a consequence of a
defect of regulatory T cells. Leukemic B cells might contrib-
ute to autoimmune complications through aberrant anti-
genic presentation [28]. Because AIHA is reported to be
more frequent in advanced CLL, an increased risk of AIHA
(and generally of AIC) in patients with ZAP-70 expression
could be related to a more aggressive disease behavior
and more profound immune defect. In CLL, different types
of AIC are probably strictly correlated. In fact, in our series,
risk factors for both AIHA and AITP were similar and clini-
cal manifestations not infrequently overlapping as in Evans
Syndrome or in cases of AITP occurring after AIHA or vice-
versa.
The impact of treatment and in particular of purine ana-
logs on AIHA occurrence in CLL patients is controversial.
An increased risk of severe AIHA in CLL patients receiving
ﬂudarabine and other purine analogs has been extensively
reported [11,12]. In our series, treatment did not seem to
increase signiﬁcantly the risk of AIC development. Never-
theless, consisting with previous observations [3,10], AIC
was more frequent in patients treated only with CLB or
FLU alone as compared with those receiving FC.
The impact of AIHA and generally of AIC on CLL progno-
sis is controversial. The majority of reports [1,2,5] found
that AIHA had no independent effect on OS. However,
Dearden et al. [4], recently reported inferior survival for
patients developing AIHA or with positive DAT on a large
prospective series. Also, AITP was recently reported to
have an adverse inﬂuence on survival in patients with CLL
Figure 3. Overall Survival according to the occurrence of autoimmune cytopenia
(290 patients).
Figure 4. Overall Survival according to the occurrence of autoimmune cytopenia
and ZAP-70 expression (290 patients).
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[6]. Our data are consistent with a negative impact of AIC
on survival of patients with CLL, although only at univariate
analysis. Interestingly, this adverse impact on survival
seemed limited to ZAP-70 positive patients, suggesting that
the occurrence of AIC could worsen the unfavourable inﬂu-
ence of this prognostic marker. The adverse inﬂuence of
AIC on survival could be related to the need of immunosup-
pressive therapy and, consequently, to the higher risk of in-
fectious complications.
In conclusion, we conﬁrm that AIC represent a common
complication of CLL during the disease course, and we
show that their occurrence is associated with adverse bio-
logical prognostic factors, occurring in older patients and in
patients with ZAP-70 positive expression and unmutated
IGHV genes. In this subset of CLL patients, the high risk of
AIC should be taken into account in the clinical manage-
ment and treatment planning.
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